Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 3/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | CPN1 | P15169 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11143478 | 0.84 | EPHX1 (0.51) | EPHX1P4HTMCYP1A2CPA1CHRM1 | |
| SCHEMBL2891180 | 0.84 | AKR1C3 (0.47) | PTGS1CPN1CPB2 | |
| SCHEMBL67234 | 0.82 | EPHX1 (0.71) | EPHX1P4HTMCYP1A2CPA1CHRM1 | |
| SCHEMBL3079795 | 0.82 | EPHX1 (0.71) | EPHX1P4HTMCYP1A2CPA1CHRM1 | |
| SCHEMBL599399 | 0.82 | EPHX1 (0.71) | EPHX1P4HTMCYP1A2CPA1CHRM1 | |
| SCHEMBL4719282 | 0.82 | EPHX1 (0.53) | EPHX1P4HTMCYP1A2CPA1ALPI | |
| SCHEMBL4272232 | 0.81 | SLC6A2 (0.58) | EPHX1P4HTMCHRM1ALPIPKM | |
| Hydrochloric Acid SCHEMBL933353 | 0.81 | EPHX1 (0.69) | EPHX1P4HTMCYP1A2CPA1CHRM1 | |
| SCHEMBL8869646 | 0.81 | MEN1 (0.64) | EPHX1P4HTMCYP1A2MEN1KMT2A | |
| SCHEMBL11842694 | 0.80 | EPHX1 (0.47) | EPHX1P4HTMCYP1A2CPA1ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20130030031-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8357716-B2 | Pyrazole derivatives used as CCR4 receptor antagonists | GLAXO GROUP LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8304446-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| EP-2401270-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | CCR4, CCR3, CCR1 | EPHX1 1549/4885P4HTM 1826/4885CYP1A2 590/4885 |
| US-20130030031-A1 | Novel Compounds | CYP3A4, CYP3A43, ABCG2 | EPHX1 1864/4885P4HTM 2929/4885CYP1A2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.